Waters (NYSE:WAT – Get Free Report) updated its fourth quarter 2024 earnings guidance on Friday. The company provided earnings per share guidance of 3.900-4.100 for the period, compared to the consensus earnings per share estimate of 4.090. The company issued revenue guidance of $846.5 million-$862.9 million, compared to the consensus revenue estimate of $853.3 million. Waters also updated its FY 2024 guidance to 11.670-11.870 EPS.
Waters Trading Down 0.6 %
Shares of Waters stock traded down $2.23 during trading on Monday, hitting $384.98. 541,333 shares of the company were exchanged, compared to its average volume of 429,799. The firm has a market capitalization of $22.85 billion, a P/E ratio of 36.74, a price-to-earnings-growth ratio of 6.35 and a beta of 0.97. The firm’s fifty day moving average price is $342.04 and its 200 day moving average price is $325.28. The company has a debt-to-equity ratio of 1.42, a current ratio of 2.10 and a quick ratio of 1.42. Waters has a 1-year low of $241.95 and a 1-year high of $391.00.
Waters (NYSE:WAT – Get Free Report) last issued its earnings results on Friday, November 1st. The medical instruments supplier reported $2.93 EPS for the quarter, beating the consensus estimate of $2.68 by $0.25. The firm had revenue of $740.30 million during the quarter, compared to the consensus estimate of $712.99 million. Waters had a net margin of 20.71% and a return on equity of 56.81%. The business’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.84 earnings per share. As a group, sell-side analysts expect that Waters will post 11.6 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on WAT
Waters Company Profile
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Further Reading
- Five stocks we like better than Waters
- What Are Dividend Champions? How to Invest in the Champions
- Intel: Is Now the Time to Be Brave?Â
- Airline Stocks – Top Airline Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Are Dividend Challengers?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.